Skip to main navigation
MBX Bio Logo
  • Our Science
    • How PEPs™ Work
    • Development Programs
  • Platform
    • Our Pipeline
      • Canvuparatide
      • MBX 4219
      • MBX 5765
      • MBX 6XXX
  • Patients
    • Current Clinical Trials
    • Patient Stories
    • Resources & Advocacy
  • About Us
    • Mission
    • Core Values
    • Leadership Team
    • Board of Directors
    • Scientific Advisory Board
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact IR
  • Careers
  • Contact Us

News Releases

May 26, 2026
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
May 11, 2026
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
May 7, 2026
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
May 7, 2026
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
April 23, 2026
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
April 3, 2026
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 12, 2026
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
March 10, 2026
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
March 9, 2026
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
February 23, 2026
MBX Biosciences to Participate in Upcoming March Investor Conferences
  • Current page 1
  • Page 2
  • Next page ›
  • Last page »
Displaying 1 - 10 of 13
MBX Bio Logo

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics.

FOLLOW US

LinkedIn Logo

©2026 MBX Bio. All Rights Reserved.

  • Contact Us
  • Privacy Policy
  • Terms of Use

Website design by Mentus

©2026 MBX Bio. All Rights Reserved.

Website design by Mentus